PharmaMar S.A. Release: FDA Grants IND For FDA’s ZALYPSISÒ To Enter Phase I Clinical Trials In US

PharmaMar announced today that its Investigational New Drug application (IND) has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis® (PM00104/50), PharmaMar's novel marine anti-tumour agent.